Retatrutide is a triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously
Ozempic Class * GLP-1 receptor agonist (Glucagon-like peptide-1 receptor agonist) Generic Name * Semaglutide Indications * Type 2 diabetes mellitus * Reduction of cardiovascular risk in selected patients with type 2 diabetes and cardiovascular disease * Weight loss (semaglutide is also marketed in some settings under a different brand for obesity management) Mechanism of Action * Stimulates glucose-dependent insulin secretion * Suppresses glucagon secretion * Delays gastric emptying * Increases satiety and reduces appetite Dosage (Type 2 Diabetes) * 0.25 mg subcutaneously once weekly for 4 weeks * Increase to 0.5 mg once weekly * May increase further based on response and local prescribing guidance Adverse Effects Common * Nausea * Vomiting * Diarrhea * Constipation * Abdominal pain * Reduced appetite Serious * Acute pancreatitis * Gallbladder disease * Acute kidney injury (usually secondary to dehydration) * Severe gastrointestinal symptoms Contraindications * Hypersensitivity to semaglutide * Personal or family history of medullary thyroid carcinoma * Multiple endocrine neoplasia syndrome type 2 (MEN2) Precautions * History of pancreatitis * Severe gastrointestinal disease * Renal impairment with significant dehydration risk Drug Interactions * May affect absorption of oral medications due to delayed gastric emptying * Risk of hypoglycemia increases when used with insulin or sulfonylureas Monitoring * HbA1c * Fasting/random blood glucose * Weight * Renal function if significant GI side effects occur * Active ingredient: Semaglutide * Administration: Subcutaneous injection once weekly * Causes significant weight loss and improves glycemic control
The FDA's period of enforcement discretion regarding certain compounded GLP-1 preparations the accommodation created while the approved products were in shortage ended in 2025, on staged dates in February and March for tirzepatide and April and May for semaglutide
Acetylcholine in the brain promotes the conduction of brain nerves and accelerates information transmission
An NMR lipid analysis includes a standard lipid profile, (LDL-C, HDL-C, triglycerides, and total cholesterol) plus the following important measurements: LDL particle number Number of small LDL particles HDL particle number LDL particle size An analysis of insulin sensitivity based on lipid particle chemistry Other parameters that can offer insight into cardiovascular risk associated with blood lipids include: Lipoprotein (a) Lp-PLA2 (which measures activity of an enzyme that can contribute to vascular plaque rupture) However, as stated elsewhere in this protocol, blood lipids represent only some of the factors that can contribute to cardiovascular risk
This can be attributed to the limited impact of semaglutide on both metabolic syndrome and the inflammatory state in the liver, unlike our treatment
